Gene sequence construct for gene therapy of human immunodeficiency virus infection
AssigneeKanglin Biotechnology (Hangzhou) Co., Ltd.
InventorsHaoquan Wu, Baozhen Sun, Ying Dang
Life of this patent
Estimating the term…
Loading patent…
AssigneeKanglin Biotechnology (Hangzhou) Co., Ltd.
InventorsHaoquan Wu, Baozhen Sun, Ying Dang
Estimating the term…
A gene sequence construct for gene therapy of human immunodeficiency virus (HIV) infection. By sequentially linking, by means of a coding sequence of a linker polypeptide, gene coding sequences of respective single-chain variable fragment (scFv) regions of light chains and heavy chains of monoclonal antibodies having different binding site antigens involved in different steps of infecting human CD4+T cells by an HIV, gene coding sequences of respective scFv regions of light chains and heavy chains of monoclonal antibodies bound to a CD4 receptor site, and a gene coding sequence of a polypeptide for inhibiting the fusion of an HIV and a CD4+T cell membrane, a gene sequence construct is constructed in a promoter and downstream of a secretory signal peptide coding sequence to express a secretory antibody-like protein molecule coded by a single gene. The recombinant single-gene construct can be conveniently introduced into a target tissue cell by means of a viral vector, and a secretory expression antibody or antibody-like protein molecule has multi-antigen antigen tropism, and can effectively and widely block an infection process of an HIV on human CD4+T cells by binding to a plurality of binding sites involved in different steps of infecting human CD4+T cells by an HIV, and effectively avoid losing an HIV infection inhibition capability due to the escape mutation of an HIV, thereby achieving a long-term or even permanent treatment effect on HIV infection by single injection administration.
A gene sequence construct for gene therapy of HIV infection, comprising one or more gene coding sequences of a single-chain antibody molecule (including a nanobody) without a constant region that has the ability to inhibit HIV infection and one or more gene coding sequences of a polypeptide (consisting of 2-50 amino acid residues) with the ability to inhibit HIV infection, to achieve the expression of a fusion protein molecule comprising the antibody molecule and the polypeptide against HIV infection encoded by a single gene, which has two or more than two target sites.
A viral vector genome comprising the construct of any one of the preceding claims.
Dependencies are inferred from the claim text.